Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion type Assertion NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_head.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion wasGeneratedBy ECO_0000203 NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_provenance.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion wasDerivedFrom befree-20150227 NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_provenance.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion SIO_000772 24685829 NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_provenance.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion evidence source_evidence_literature NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_provenance.
- NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_assertion description "[Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and docetaxel.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379575.RAaW6cu6r0LAkgbspba8m9sZYLu-EsZY1oIdiJgBwB_4o130_provenance.